Novo Nordisk
About the company
The company profile is sourced from neutral references (Wikipedia, official filings) so this page stays a reference, not an opinion. Our own coverage is in the regulatory history and cases below.
Violations & regulatory history
| Date | Regulator | Type | Fine |
|---|---|---|---|
| Jan 1, 2023 | DOJ | Deferred prosecution agreement | $221,000,000 |
Cases we track
Products & services involved
- Semaglutide (Ozempic / Wegovy) (manufacturer)
Frequently asked questions
What cases is Novo Nordisk involved in?
We currently track 1 matter involving Novo Nordisk: GLP-1 NAION (Semaglutide Vision Loss). Each links to the full case record with court, status and settlement information.
What has the regulator found about Novo Nordisk?
Our regulatory history table lists 1 recorded item — actions, settlements and penalties with the regulator, date and amount where published. Every row links to its source.
Where does the Novo Nordisk information come from?
Company profiles are sourced from neutral references: Wikipedia, official company websites and filings, and regulator records. Our own coverage is the regulatory history table and the case links below.
Affected by Novo Nordisk products?
Check the case record and start a free review on the relevant case page: GLP-1 NAION (Semaglutide Vision Loss) →